Respiratory syncytial virus (RSV) causes annual epidemics of respiratory infection. Usually harmless to adults, the RSV infection can be dangerous to children under 3 years of age and elderly people over 65 years of age, often causing serious problems, even death. At present, there are no vaccines and specific chemotherapeutic agents for the treatment of this disease, so the search for low-molecular weight compounds to combat RSV is a challenge. In this work, we have shown, for the first time, that monoterpene-substituted arylcoumarins are efficient RSV replication inhibitors at low micromolar concentrations. The most active compound has a selectivity index of about 200 and acts most effectively at the early stages of infection. The F protein of RSV is a potential target for these compounds, which is also confirmed by molecular docking and molecular dynamics simulation data.
呼吸道合胞病毒(RSV)每年都会引起呼吸道感染流行。通常情况下,RSV 对成人无害,但对 3 岁以下儿童和 65 岁以上老人来说,RSV 感染可能很危险,往往会造成严重问题,甚至死亡。目前,还没有治疗这种疾病的疫苗和特异性化疗药物,因此寻找抗 RSV 的低分子量化合物是一项挑战。在这项研究中,我们首次发现单萜取代的芳基香豆素类化合物在低微摩尔浓度下是高效的 RSV 复制抑制剂。活性最高的化合物的选择性指数约为 200,在感染的早期阶段发挥最有效的作用。RSV 的 F 蛋白是这些化合物的潜在靶标,分子对接和分子动力学模拟数据也证实了这一点。